[ad_1]
SINGAPORE, Dec. 7, 2025 /PRNewswire/ — ChemLex, a next-generation AI-for-science corporate, as of late introduced the status quo of its world headquarters and self-driving laboratory in Singapore, along the related of a USD 45 million investment spherical led via Granite Asia.
Based in 2022, ChemLex develops AI applied sciences that radically boost up chemical discovery for the pharmaceutical trade, considerably decreasing time-to-market. In simply 3 and a part years, it has grown to aid greater than 70 shoppers international, together with six of the arena’s lead ten pharmaceutical corporations. This surge displays a bigger trade shift as analysts be expecting the AI-powered drug discovery marketplace to leap from USD 3.6B in 2024 to nearly USD 50B by 2034.
On the core of ChemLex’s platform is a 24/7 self sustaining chemistry machine that speeds up chemical discovery, making it way more cost-efficient and considerably extra sustainable than conventional laboratory forms. Using that is an cutting edge AI-powered, totally automatic synthesis sequence, which runs experiments autonomously, captures information in real-time, and transforms chemical discovery from a stop-start procedure right into a easy workflow.
The unused investment will aid the hiring of extra {hardware} and instrument engineers, in addition to chemists in Singapore, enabling the corporate to handover a broader pipeline of pharmaceutical and fabrics science initiatives.
Sean Lin, Founder and CEO of ChemLex: “We’re building an R&D engine that compresses months of synthesis and optimisation into weeks or even days, transforming both the speed and certainty of discovery. Singapore strengthens this effort and provides us an ecosystem to scale rapidly and support partners globally who need this capability now.”
Yinghui Kuang, Spouse at Granite Asia: “AI-enabled chemistry is creating one of the most important industrial transitions of the decade, and ChemLex sits in that sweet spot, turning that shift into a business advantage with a platform that can accelerate molecule design and manufacturing at scale. This is the type of deeptech company that can reshape supply chains, shorten development timelines, and unlock new economic value, and Singapore gives them the foundation to grow.”
ChemLex additionally signed a memorandum of figuring out with the Experimental Drug Development Centre (EDDC), Singapore’s nationwide platform for drug discovery and construction. This collaboration seeks to boost up next-generation petite molecule drug discovery thru complex automation.
Prof. Damian O’Connell of the Experimental Drug Construction Centre: “We first met ChemLex in 2023, and since then we’ve seen the company grow from a promising startup to a global innovator in AI and automation-driven chemical synthesis. As ChemLex’s first Singapore partner, we are thrilled to expand our collaboration through the MOU. This partnership reinforces our shared vision of accelerating drug discovery and development through cutting-edge technology, ultimately bringing safer, more effective therapies to patients faster. By combining EDDC’s drug development expertise with ChemLex’s automation and AI capabilities, we aim to shorten timelines, reduce costs, and deliver innovative treatments that improve lives in Singapore and globally.”
Those projects align with the Singapore Financial Construction Board’s (EDB) efforts to create a extra resilient, innovation-ready year sciences ecosystem.
Goh Wan Yee, Senior Vice President and Head, Healthcare, Financial Construction Board: “ChemLex’s decision to anchor its global R&D headquarters and AI laboratory in Singapore reflects how companies can leverage the confluence of our strengths in deep tech and biomedical sciences ecosystem, to launch breakthrough innovations. We look forward to supporting more like-minded partners like ChemLex, to accelerate scientific discoveries that will benefit patients worldwide.”
SOURCE ChemLex
[ad_2]
Source link
